RxDoctor Payments Data

Melanie Cardoza, DO

Internal Medicine · Fall River, MANPI 1427007921

Payments from drug & device makers

$6,632in general payments, 2019–2025

Across 403 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$985
  • Pfizer$942
  • AbbVie$619
  • Novo Nordisk$563
  • Abbott$458
  • Merck$360
  • plus $3K from 40 others

What the payments were for

  • Speaking & faculty fees$601%
  • Food & beverage$6,52098%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,632 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$143,753
Medicare patients
222
Services billed
1,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$43,414
JardianceEmpagliflozin31$42,813
TradjentaLinagliptin62$41,303
JanuviaSitagliptin Phosphate39$37,791
OzempicSemaglutide19$18,368
XareltoRivaroxaban19$13,746
FarxigaDapagliflozin Propanediol19$13,456
NexiumEsomeprazole Magnesium13$13,110
TrintellixVortioxetine Hydrobromide15$9,220
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$5,601
Humalog Kwikpen U-100Insulin Lispro14$3,899
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,501
Rosuvastatin Calcium71$1,734
Albuterol Sulfate HfaAlbuterol Sulfate47$1,450
Lidocaine18$1,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$276$84,11693 claims
PfizerEliquis$942$43,41469 claims
MerckJanuvia$360$37,79139 claims
AstraZenecaFarxiga, Nexium$985$26,56532 claims
Novo NordiskOzempic$563$18,36819 claims
Johnson & JohnsonXarelto$258$13,74619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →